person · Reporting owner
Ghodadra Neilesh Shailesh
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Turn Therapeutics Inc.TTRX · Entity 5935 | Director · Chief Medical Officer | October 08, 2025 | October 10, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Turn Therapeutics Inc.
Report date October 08, 2025 · Filed October 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,000 |
Reported balance
After 2025-10-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-10-08 · Grant · Acquired 10,000 · Balance 10,000 F1: Reflects an award of restricted stock units ("RSUs") granted under the Issuer's 2025 Omnibus Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. These RSUs will vest upon the earlier of the first anniversary of the grant date or a change in control of the Issuer, in each case, subject to the reporting person's continuous service through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an award of restricted stock units ("RSUs") granted under the Issuer's 2025 Omnibus Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. These RSUs will vest upon the earlier of the first anniversary of the grant date or a change in control of the Issuer, in each case, subject to the reporting person's continuous service through the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 08, 2025 Filed Oct 10, 2025 09:43 UTC | Turn Therapeutics Inc. TTRX · Entity 5935 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-098571 · tm2528487-5_4seq1.xml · nonDerivative · entry 1 Ghodadra Neilesh Shailesh · CIK 0002089048 · Director · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 F1 · security: Reflects an award of restricted stock units ("RSUs") granted under the Issuer's 2025 Omnibus Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. These RSUs will vest upon the earlier of the first anniversary of the grant date or a change in control of the Issuer, in each case, subject to the reporting person's continuous service through the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.